slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 234,181-234,210
Pages 10,126
Rows per page 30
Component
234,181-234,210 of 303,780
13
The slide uses a timeline-based framework to map treatment lines (1L, 2L, 3L+) against clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a matrix-style comparison to highlight the superior coverage of NVL-655 compared to 1st, 2nd, and 3rd generation inhibitors.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed patient enrollment breakdown by dose cohort and trial phase.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Includes a table detailing patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a visual comparison matrix to highlight the therapeutic advantages of Zidesamtinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate competitive superiority in potency, CNS penetration, and selectivity.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data from ARROS-1 Phase 1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide highlights the Recommended Phase 2 Dose (RP2D) selection based on safety and PK data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
40
The slide uses dot plots to show IC50 and selectivity index across various cell lines, and a bar chart for brain exposure in rats.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
41
The slide uses a timeline framework to connect current clinical status to the 'OnTarget 2026' mission.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Oatly | Results Presentation Deck | 43 slidesOatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit
03
Oatly | Results Presentation Deck | 43 slidesOatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit
04
Oatly | Results Presentation Deck | 43 slidesOatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit
05
Includes a footnote regarding non-IFRS measures.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Attention1 hit
06
The slide uses a combination of bar charts to illustrate financial performance trends.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations Beat · Need1 hit
07
The slide uses a stylized robot icon as a speech bubble anchor for the main headline.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit
08
The slide uses a three-column layout with visual callouts for each focus area.Oatly | Results Presentation Deck | 43 slides · Oatly
Conference presentation Investor relations 1 hit